Trilateral retinoblastoma: incidence and outcomes
Part of Cancer, Eyes & vision clinical trials.
This study looks at how often trilateral retinoblastoma (a rare form that affects the brain as well as the eye) happens and what the outcomes are. It may help doctors better understand this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child has been diagnosed with retinoblastoma, a type of eye cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how retinoblastoma and its treatment affect thinking skills and quality of life over time. It may help doctors better support survivors and their families.
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
This study looks at long-term health outcomes—how patients are doing physically and in daily life—after treatment for retinoblastoma. It may help doctors understand what support or follow-up care could be most helpful after treatment.
This study looks at gene changes in retinoblastoma to understand why some tumors spread outside the eye. It may help find better ways to predict and treat the disease.
This study looks at patients who have received additional cancer treatment after their initial retinoblastoma (eye cancer) therapy and tracks their recovery for at least one year. The research aims to understand how well this follow-up treatment works and what happens to patients over time.
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
Hear when a new Retinoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.